Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract 2407: Neuroendocrine and luminal progenitors drive cancer progression in prostate cancer

Maximilian Marhold, Erwin Tomasich, Simon Udovica, Gerwin Heller, Corinna Altenberger, Andreas Spittler, Reinhard Horvat, Peter Horak, Michael Krainer

Cancer Res (2016) 76 (14_Supplement): 2407.

https://doi.org/10.1158/1538-7445.AM2016-2407

Published: 15 July 2016

View article titled, Abstract 2407: Neuroendocrine and luminal progenitors drive cancer progression in prostate cancer

Journal Articles

Abstract 2697: Drug combinations for breast cancer based on synthetic lethality screens in yeast

Michael Schwarz, Erwin Tomasich, Maximilian Marhold, Andreas Heinzel, Paul Perco, Peter Horak, Bernd Mayer, Michael Krainer

Cancer Res (2016) 76 (14_Supplement): 2697.

https://doi.org/10.1158/1538-7445.AM2016-2697

Published: 15 July 2016

View article titled, Abstract 2697: Drug combinations for breast cancer based on synthetic lethality screens in yeast

Journal Articles

Abstract 3047: Hypoxia leads to deregulation of PI3K/AKT/mTOR signaling in prostate cancer stem cells

Maximilian Marhold, Erwin Tomasich, Zuzana Pernicová, Radek Fedr, Karel Soucek, Andreas Spittler, Michael Krainer, Peter Horak

Cancer Res (2014) 74 (19_Supplement): 3047.

https://doi.org/10.1158/1538-7445.AM2014-3047

Published: 01 October 2014

View article titled, Abstract 3047: Hypoxia leads to deregulation of PI3K/AKT/mTOR signaling in prostate cancer stem cells

Journal Articles

Abstract LB-201: Prostate cancer stem cells display low mTOR activity and resistance to mTOR inhibitors in hypoxia

Maximilian Marhold, Erwin Tomasich, Günther Hofbauer, Michael Krainer, Peter Horak

Cancer Res (2012) 72 (8_Supplement): LB-201.

https://doi.org/10.1158/1538-7445.AM2012-LB-201

Published: 15 April 2012

View article titled, Abstract LB-201: Prostate cancer stem cells display low mTOR activity and resistance to mTOR inhibitors in hypoxia

Journal Articles

Abstract 3997: TUSC3 (N33) affects protein N-glycosylation and proliferation of prostate cancer cells

Peter Horak, Erwin Tomasich, Mariam Anees, Maximilian Marhold, Marion Gerschpacher, Dietmar Pils, Michael Krainer

Cancer Res (2012) 72 (8_Supplement): 3997.

https://doi.org/10.1158/1538-7445.AM2012-3997

Published: 15 April 2012

View article titled, Abstract 3997: TUSC3 (N33) affects protein N-glycosylation and proliferation of prostate cancer cells

Journal Articles

Abstract 3661: The impact of tumor-infiltrating natural killer cells on ovarian cancer progression

Ahmed El-gazzar, Eva Eckelhart, Paul Perco, Reinhard Horvat, Veronika Sexl, Michael Krainer

Cancer Res (2011) 71 (8_Supplement): 3661.

https://doi.org/10.1158/1538-7445.AM2011-3661

Published: 15 April 2011

View article titled, Abstract 3661: The impact of tumor-infiltrating natural killer cells on ovarian cancer progression

Journal Articles

Abstract 4777: Loss of death receptor 5 expression in plasmacytic MALT lymphoma is associated with genetic aberrations

Mariam Anees, Peter Horak, Leonhard Müllauer, Berthold Streubel, Markus Raderer, Michael Krainer

Cancer Res (2011) 71 (8_Supplement): 4777.

https://doi.org/10.1158/1538-7445.AM2011-4777

Published: 15 April 2011

View article titled, Abstract 4777: Loss of death receptor 5 expression in plasmacytic MALT lymphoma is associated with genetic aberrations

Journal Articles

Abstract #5127: FLIP shows a dual impact on ovarian cancer (OC) development: chaperoning OC cells from immunosurveillance and increasing their invasive potential

Ahmed El-gazzar, Paul Perco, Michael Wittinger, Reinhard Horvat, Wolfgang Mikulits, Bernd Mayer, Michael Krainer

Cancer Res (2009) 69 (9_Supplement): 5127.

Published: 01 May 2009

View article titled, Abstract #5127: FLIP shows a dual impact on ovarian cancer (OC) development: chaperoning OC cells from immunosurveillance and increasing their invasive potential

Journal Articles

Abstract #5128: Characterization of the TRAIL pathway in a syngeneic mouse model of ovarian cancer

Ahmed El-gazzar, Mariam Anees, Reinhard Horvat, Bernd Mayer, Michael Krainer

Cancer Res (2009) 69 (9_Supplement): 5128.

Published: 01 May 2009

View article titled, Abstract #5128: Characterization of the TRAIL pathway in a syngeneic mouse model of ovarian cancer

Journal Articles

HCRP1 contributes to degradation of activated EGFR, a mechanism highly relevant for ovarian cancer

Michael Wittinger, Dietmar Pils, Ahmed El-Gazzar, Robert Zeillinger, Thomas Grunt, Michael Krainer

Cancer Res (2008) 68 (9_Supplement): 3427.

Published: 01 May 2008

View article titled, HCRP1 contributes to degradation of activated EGFR, a mechanism highly relevant for ovarian cancer

Journal Articles

Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers

Lin Li, Stephan Ryser, Eva Dizin, Dietmar Pils, Michael Krainer, Charles Edward Jefford, Francesco Bertoni, Robert Zeillinger, Irmgard Irminger-Finger

Cancer Res (2007) 67 (24): 11876–11885.

https://doi.org/10.1158/0008-5472.CAN-07-2370

Published: 18 December 2007

View article titled, Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers

Includes: Supplementary data

Journal Articles

Whole genome screening for epigenetically silenced genes using a panel of epithelial cancer cell lines

Dietmar Pils, Brigitte Wolf, Michael Wittinger, Jochen Reibenwein, Bernd Mayer, Dominique Koensgen, Alexander Mustea, Isabelle Cadron, Toon van Gorp, Sven Mahner, Nicole Concin, Dan Cacsire-Castillo Tong, Robert Zeillinger, Michael Krainer

Cancer Res (2007) 67 (9_Supplement): 251.

Published: 01 May 2007

View article titled, Whole genome screening for epigenetically silenced genes using a panel of epithelial cancer cell lines

Journal Articles

N33 (TUSC3) promoter hypermethylation in serum of prostate cancer patients

Peter Horak, Jochen Reibenwein, Dietmar Pils, Alexey Teterin, Andreas Kirisits, Katarzyna Elandt, Sandra Tomek, Christoph C. Zielinski, Michael Krainer

Cancer Res (2006) 66 (8_Supplement): 763–764.

Published: 15 April 2006

View article titled, N33 (TUSC3) promoter hypermethylation in serum of prostate cancer patients

Journal Articles

Hypermethylation of N33 (TUSC3) as independent molecular predictor for ovarian cancer

Dietmar Pils, Peter Horak, Andreas Kirisits, Andreas Gleiss, Markus Omann, Alexander Pinter, Christoph Zielinski, Alexander Mustea, Dominique Koensgen, Robert Zeillinger, Michael Krainer

Cancer Res (2006) 66 (8_Supplement): 760.

Published: 15 April 2006

View article titled, Hypermethylation of N33 (TUSC3) as independent molecular predictor for ovarian cancer

Journal Articles

TRAIL receptor 1 (DR4) is frequently methylated in ovarian cancer: Relevance for TRAIL sensitivity and ovarian cancer tumorigenesis

Peter Horak, Dietmar Pils, Griet Haller, Reinhard Horvath, Sandra Tomek, Robert Zeillinger, Christoph Zielinski, Michael Krainer

Cancer Res (2005) 65 (9_Supplement): 586–587.

Published: 01 May 2005

View article titled, TRAIL receptor 1 (DR4) is frequently methylated in ovarian cancer: Relevance for TRAIL sensitivity and ovarian cancer tumorigenesis

Journal Articles

Common Nonsense Mutations in RAD52

Daphne W. Bell, Doke C. R. Wahrer, Deborah H. Kang, Melissa S. MacMahon, Michael G. FitzGerald, Chikashi Ishioka, Kurt J. Isselbacher, Michael Krainer, Daniel A. Haber

Cancer Res (1999) 59 (16): 3883–3888.

Published: 15 August 1999

View article titled, Common Nonsense Mutations in RAD52

Journal Articles

Predictive Value of Interleukin-6 and Neopterin in Patients with Multiple Myeloma

Gilbert Reibnegger, Michael Krainer, Manfred Herold, Heinz Ludwig, Helmut Wachter, Heinz Huber

Cancer Res (1991) 51 (23_Part_1): 6250–6253.

Published: 12 January 1991

View article titled, Predictive Value of Interleukin-6 and Neopterin in Patients with Multiple Myeloma

NARROW

Abstract 2407: Neuroendocrine and luminal progenitors drive cancer progression in prostate cancer

Abstract 2697: Drug combinations for breast cancer based on synthetic lethality screens in yeast

Abstract 3047: Hypoxia leads to deregulation of PI3K/AKT/mTOR signaling in prostate cancer stem cells

Abstract LB-201: Prostate cancer stem cells display low mTOR activity and resistance to mTOR inhibitors in hypoxia

Abstract 3997: TUSC3 (N33) affects protein N-glycosylation and proliferation of prostate cancer cells

Abstract 3661: The impact of tumor-infiltrating natural killer cells on ovarian cancer progression

Abstract 4777: Loss of death receptor 5 expression in plasmacytic MALT lymphoma is associated with genetic aberrations

Abstract #5127: FLIP shows a dual impact on ovarian cancer (OC) development: chaperoning OC cells from immunosurveillance and increasing their invasive potential

Abstract #5128: Characterization of the TRAIL pathway in a syngeneic mouse model of ovarian cancer

HCRP1 contributes to degradation of activated EGFR, a mechanism highly relevant for ovarian cancer

Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers

Whole genome screening for epigenetically silenced genes using a panel of epithelial cancer cell lines

N33 (TUSC3) promoter hypermethylation in serum of prostate cancer patients

Hypermethylation of N33 (TUSC3) as independent molecular predictor for ovarian cancer

TRAIL receptor 1 (DR4) is frequently methylated in ovarian cancer: Relevance for TRAIL sensitivity and ovarian cancer tumorigenesis

Common Nonsense Mutations in RAD52

Predictive Value of Interleukin-6 and Neopterin in Patients with Multiple Myeloma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only